Antibody Drug Conjugates (ADCs) are designed to deliver cytotoxins to cancer cells, and they can be used to treat solid tumours as well as hematologic cancers. ADCs are kind of biopharmaceutical medications meant for treatment of various type of cancers. ADCs are designed in such a way that they can descriminate between infected cells and normal cells. An ADC can target and bind to cell-surface proteins found on cancer cells, then release its cell-killing drugs with the help of a linker. This characteristic allows ADCs to destroy cancer cells selectively while limiting side effects for patients.
The "Global Antibody Drug Conjugates Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the antibody drug conjugates market with detailed market segmentation by technology and application. The report provides key statistics on the market status of the leading antibody drug conjugates market players and offers key trends and opportunities in the market.
- Based on technology the market is segmented as, cleavable linker and non-cleavable linker.
- Based on application the market is segmented as, blood cancer, brain cancer, breast cancer, ovarian cancer and lung cancer.
- Increasing prevalence of cancers such as, solid tumors, haematological disorders are the major driving factors for the market growth.
- Rising geriatric population across the globe.
- Presence of strong pipeline of therapeutic agents are also expected to spur the market growth.
- Extensive R&D efforts for development of novel drug therapies such as ADCs, immunotherapies for management of chronic diseases.
- However, risk of possibel side effects associated with the treatment are expected to restrain market growth during the forecast period.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The antibody drug conjugates market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the antibody drug conjugates market in these regions.
IMPACT OF COVID-19 ON ANTIBODY DRUG CONJUGATES MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for antibody drug conjugates and related therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for antibody drug conjugates. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
The report covers key developments in the antibody drug conjugates market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from antibody drug conjugates market are anticipated to lucrative growth opportunities in the future with the rising demand for antibody drug conjugates in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the antibody drug conjugates market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- AbbVie Inc.
- Baxter International Inc
- Cerbios-Pharma SA
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Pfizer Inc.
- Piramal Pharma Solutions
- Syngene International Limited
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.